Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8998604 | Neuropharmacology | 2005 | 10 Pages |
Abstract
The subunit composition and pharmacology of α-Conotoxin MII-binding (α-CtxMII) nicotinic acetylcholine receptors (nAChR) was studied by an improved [125I]-α-CtxMII membrane binding method. This binding method facilitates pharmacological studies that have been difficult to accomplish with [125I]-α-CtxMII autoradiography or α-CtxMII inhibition of [125I]-epibatidine binding. Binding densities and Kd-values obtained by this [125I]-α-CtxMII membrane binding were similar to the values obtained by autoradiography or α-CtxMII inhibition of [125I]-epibatidine binding, verifying that each of these approaches measures the same nAChR population. Binding results with nAChR subunit-null mutant mice confirm and extend observations from earlier studies: [125I]-α-CtxMII binding measures two sets of α6β2* nAChR (α4α6β2β3 or α6β2β3). Most nicotinic agonists and antagonists show monophasic inhibition of [125I]-α-CtxMII binding, indicating that α4α6β2β3 and α6β2β3 have similar binding properties. Comparison of the binding and activation profiles of α6β2* nAChR to those of other nAChR subtypes (α4β2* and β4*) indicates that these receptors have distinctly different pharmacology indicating that it may be possible to target α6β2* nAChR selectively to develop compounds that might be therapeutically useful.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Outi Salminen, Paul Whiteaker, Sharon R. Grady, Allan C. Collins, J. Michael McIntosh, Michael J. Marks,